Stockscreener 앱 받기
5.14
5.78%
-0.40
전일 마감가:
$5.54
열려 있는:
$5.34
하루 거래량:
6.06M
Relative Volume:
226.63
시가총액:
$3.80M
수익:
$2,000
순이익/손실:
$-12.72M
주가수익비율:
-0.0716
EPS:
-71.8121
순현금흐름:
$-3.91M
1주 성능:
+3.78%
1개월 성능:
+17.04%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.74
$5.5699
1주일 범위
$4.45
$6.1175
52주 변동 폭
$3.38
$7.56
Nexentis Technologies Inc Stock (NXTS) Company Profile
명칭
Nexentis Technologies Inc
전화
972544561349
주소
156 FIFTH AVENUE 10TH FLOOR, NEW YORK
Compare NXTS vs CTVA, NTR, CF, MOS, ICL
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTS
Nexentis Technologies Inc
|
5.20 | 4.05M | 2,000 | -12.72M | -3.91M | -71.81 |
CTVA
Corteva Inc
|
76.59 | 50.64B | 17.89B | 1.26B | 2.05B | 1.7029 |
NTR
Nutrien Ltd
|
65.19 | 31.74B | 27.83B | 2.42B | 2.21B | 4.9113 |
CF
Cf Industries Holdings Inc
|
106.55 | 16.42B | 7.41B | 2.12B | 1.62B | 11.13 |
MOS
Mosaic Company
|
22.34 | 7.16B | 12.05B | 575.40M | -534.60M | 1.6871 |
ICL
Icl Group Ltd
|
5.435 | 7.42B | 7.41B | 314.00M | 220.88M | 0.202 |
Nexentis Technologies Inc 주식(NXTS)의 최신 뉴스
Nexentis Technologies (NXTS) sells 311,876 shares; concurrent warrants issued - Stock Titan
NXTS Q2 2025 Earnings: Loss Deepens as Pre‑Revenue Phase ContinuesGrowth Acceleration Report - newsline.com
Nexentis Technologies Announces New Equity Financing Agreements - TipRanks
Nexentis Technologies Raises $1.25 Million in Registered Direct Offering, Issues 5-Year Warrants - TradingView
Nexentis Technologies (NXTS) prices $1.25M stock and warrant offerings - Stock Titan
NXTS Q2 2025 Earnings: Loss Per Share of -$0.18 Amidst Limited Financial DisclosureProfit Announcement - newsline.com
Nexentis Technologies Inc. (NXTS) Surges 10.69% as Bullish Momentum BuildsVolatility Surface - newsline.com
NXTS Q2 2025 Earnings: Loss Per Share Widens but Stock Surges on Strategic ProgressHealthcare Earnings Report - newsline.com
NXTS News | NEXENTIS TECHNOLOGIES INC (NASDAQ:NXTS) - ChartMill
NXTS Q2 2025 Earnings: Net Loss of -$0.18 Per Share Triggers Double-Digit Stock DeclineEPS Surprise History - newsline.com
Nexentis Technologies (NXTS) Earnings Date and Reports 2026 - MarketBeat
NXTS Q2 2025 Earnings: EPS Loss Narrows, Stock Surges on Operational ProgressHealthcare Earnings Report - The Legal Advocate
Nexentis Technologies (NXTS) Surges 5.1%: Key Levels and Volume Patterns Signal Potential BreakoutCalendar Spread Trade - The Legal Advocate
Nexentis Expands Credit Facility Under Amended Financing Agreement - TipRanks
Nexentis Technologies Inc. Approves Amendment to A Facility Agreement - marketscreener.com
Nexentis Technologies (NASDAQ: NXTS) expands EUR 10M credit line and warrant terms - Stock Titan
Nexentis Technologies (NXTS) Surges 15.4% – Momentum Builds Above Key SupportAAII Bullish - newsline.com
Nexentis Technologies (NXTS) Gains 1.36% as Stock Tests Key Resistance Near $4.70Low Beta Factor - thelegaladvocate.com
Nexentis Technologies (NXTS) Earnings Outlook: Key Metrics for Q2 2025Retail Trader Picks - Newser
Nexentis subsidiary achieves drug discovery milestone By Investing.com - Investing.com South Africa
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone - TipRanks
Nexentis subsidiary reaches drug discovery milestone By Investing.com - Investing.com Nigeria
Nexentis subsidiary reaches drug discovery milestone - Investing.com
Nexentis subsidiary achieves drug discovery milestone - Investing.com
Nexentis develops new molecule to potentially tackle hard-to-treat cancers - Stock Titan
Nexentis Technologies (NASDAQ: NXTS) posts Q1 2026 loss, flags going concern risk - Stock Titan
Nexentis Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nexentis Technologies Inc. Announces Drug Discovery Milestone Achieved by MitoCareX Utilizing MITOLINE® Platform - Quiver Quantitative
Nexentis Technologies Announces Optimization of Hit - GlobeNewswire
Nexentis Technologies Inc. (NXTS) - Zacks Investment Research
Number of shareholders of Nexentis Technologies Inc. – NASDAQ:NXTS - TradingView
Nexentis Technologies Secures US Trademark Approval for MitoCareX Algorithm Platform MITOLINE - ChemAnalyst
Nexentis Technologies stock jumps on trademark approval - Investing.com
Nexentis subsidiary receives U.S. trademark for drug platform By Investing.com - Investing.com South Africa
Nexentis Technologies stock jumps on trademark approval By Investing.com - Investing.com Nigeria
Nexentis subsidiary receives U.S. trademark for drug platform - Investing.com
Drug discovery firm secures U.S. trademark for its MITOLINE platform - Stock Titan
Nexentis Technologies Announces U.S. Trademark Registration - GlobeNewswire
NXTS (Nexentis Technologies) falls 2.62% after Q2 2025 earnings with no consensus performance benchmarks available.FCF Yield - newser.com
Nexentis Shareholders Approve Reverse Split and Financing Flexibility - The Globe and Mail
Shareholders back Nexentis (NITO) reverse split and equity financing plans - Stock Titan
[EFFECT] Nexentis Technologies Inc. SEC Filing - Stock Titan
NXTS Price History for Nexentis Technologies Stock - Barchart.com
Nexentis Technologies (NXTS) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Nexentis Technologies Inc. (NXTS) Cash Equivalents (Quarterly) - Zacks Investment Research
Nexentis Technologies Inc (NXTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.91%
1.16%
자본화:
|
볼륨(24시간):